Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19

Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic.

Palabras clave: COVID-19 , ELISA , RBD , SARS-COV-2 , SEROLOGICAL TEST

Ver el registro completo

Archivos asociados

Tamaño: 2.119Mb

Formato: PDF

Solicitar

Licencia

Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)

Identificadores

URI: http://hdl.handle.net/11336/163019

DOI: https://doi.org/10.1016/j.jim.2021.113182

URL: https://www.sciencedirect.com/science/article/pii/S0022175921002271

Colecciones

Articulos (IABIMO)
Articulos de INSTITUTO DE AGROBIOTECNOLOGIA Y BIOLOGIA MOLECULAR

Articulos(INBIOMED)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS

Citación

Villafañe, Luciana María; Vaulet, Lucía Gallo; Viere, Florencia M.; Klepp, Laura Ines; Forrellad, Marina Andrea; et al.; Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19; Elsevier Science; Journal Of Immunological Methods; 500; 11-2021; 1-5

Altmétricas